Literature DB >> 3338022

Ovarian mixed-epithelial papillary cystadenomas of borderline malignancy of mullerian type. A clinicopathologic analysis.

J L Rutgers1, R E Scully.   

Abstract

Borderline tumors with papillae that are architecturally similar to those of serous tumors but with a lining of more than one mullerian cell type have not been well characterized in in the literature. We have studied 36 such tumors. The patients averaged 35 years of age. Twenty-two percent of the tumors were bilateral; all were confined to the ovaries as confirmed at operation. Fifty-three percent were associated with endometriosis. Follow-up information was available on 34 patients for a mean interval of 4.8 years. A tumor developed in the contralateral ovary in one patient 2 years after unilateral salpingo-oophorectomy. Three patients had pelvic recurrences between 7 months and 3 years, but all of them were successfully treated and none have died. These tumors differ clinically and pathologically from intestinal-type mucinous borderline tumors, but they have many similarities with mullerian mucinous borderline tumors and, to a lesser extent, with serous borderline tumors.

Entities:  

Mesh:

Year:  1988        PMID: 3338022     DOI: 10.1002/1097-0142(19880201)61:3<546::aid-cncr2820610321>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Intestinal differentiation in ovarian mucinous tumours.

Authors:  N J Ball; D I Robertson; M A Duggan; D D Snider
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

2.  Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.

Authors:  Chen Hsuan Wu; Tsui-Lien Mao; Russell Vang; Ayse Ayhan; Tian-Li Wang; Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2012-07       Impact factor: 2.762

3.  Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.

Authors:  Hiroki Sasamori; Kentaro Nakayama; Sultana Razia; Hitomi Yamashita; Tomoka Ishibashi; Masako Ishikawa; Seiya Sato; Satoru Nakayama; Yoshiro Otsuki; Ritsuto Fujiwaki; Noriyoshi Ishikawa; Satoru Kyo
Journal:  Curr Oncol       Date:  2022-05-18       Impact factor: 3.109

Review 4.  Seromucinous Tumors of the Ovary. What's in a Name?

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2016-01       Impact factor: 2.762

Review 5.  Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management.

Authors:  Masaki Mandai; Ken Yamaguchi; Noriomi Matsumura; Tsukasa Baba; Ikuo Konishi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

6.  Ovarian Seromucinous Borderline Tumor and Clear Cell Carcinoma: An Unusual Combination.

Authors:  Eriko Nakamura; Yuichiro Sato; Sayaka Moriguchi; Atsushi Yamashita; Takashi Higo; Yujiro Asada
Journal:  Case Rep Obstet Gynecol       Date:  2015-05-13

Review 7.  Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues.

Authors:  Michiko Nagamine; Yoshiki Mikami
Journal:  Diagnostics (Basel)       Date:  2020-01-31

8.  Pelvic seromucinous borderline tumor 26 years after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy.

Authors:  Takashi Uehara; Hiroshi Yoshida; Tomoyasu Kato
Journal:  Gynecol Oncol Rep       Date:  2020-12-28

Review 9.  The Evolution of Ovarian Carcinoma Subclassification.

Authors:  Martin Köbel; Eun Young Kang
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.